A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Treatment with Efimosfermin in Adult Participants with Alcohol-related liver disease
Study to Evaluate the Efficacy & Safety of Treatment with Efimosfermin Alfa in Adult Participants with Alcohol-related Liver Disease (ALD)
Sponsor: GSK Research & Development Limited
Enrolling: Male and Female Patients
IRB Number: ACYY2842
Contact: Transplant Clinical Research Center: 212-305-3839 / tcrcstudyreferral@cumc.columbia.edu
Additional Study Information: Researchers at Columbia University Irving Medical Center are investigating whether the investigational medication efimosfermin is safe and effective in improving outcomes for adults with Alcohol-related Liver Disease (ALD). ALD refers to liver damage caused by heavy alcohol consumption. The study uses a placebo for comparison because there are no approved medicines yet for treating advanced chronic liver disease caused by alcohol.
This study is closed
Investigator
Gene Im, MD, FAASLD
Do You Qualify?
Are you 18 years of age and younger than 75 years of age? Yes No
Are you using a contraceptive method that is effective, with a failure rate of Yes No
For men, do you consume 5 or more standard drinks on any day or 15 or more standard drinks per week? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Transplant Clinical Research Center
tcrcstudyreferral@cumc.columbia.edu
212-305-3839